Over the coming years an increasing number of biologic medicines will lose patent protection creating both competition and headroom for governments and payers to further invest in innovation. Biologic medicines have, and continue to play a key role in disease treatment and EFPIA fully supports the creation of competitive, efficient and sustainable off-patent biologic markets as a means to help achieve these goals. However, due to their unique characteristics, it needs to be recognised that policies must be designed specifically for biological medicines.

EFPIA has developed a set of principles to help healthcare systems design and implement policies that can successfully create competitive off-patent biologic markets.